Technical Analysis for HROW - Harrow Health, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| See historical HROW trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 16 | Wide Bands | Range Expansion | 0.00% |
| Jan 16 | Down 3 Days in a Row | Weakness | 0.00% |
| Jan 16 | Down 4 Days in a Row | Weakness | 0.00% |
| Jan 15 | Wide Bands | Range Expansion | -2.03% |
| Jan 15 | Down 3 Days in a Row | Weakness | -2.03% |
| Jan 14 | Wide Bands | Range Expansion | -2.86% |
| Jan 14 | Overbought Stochastic | Strength | -2.86% |
| Jan 11 | Upper Bollinger Band Walk | Strength | -4.46% |
| Jan 11 | Inside Day | Range Contraction | -4.46% |
| Jan 11 | Wide Bands | Range Expansion | -4.46% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-13
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Harrow Health, Inc., formerly Imprimis Pharmaceuticals, Inc., is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more HROW news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.75 |
| 52 Week Low | 1.45 |
| Average Volume | 438,747 |
| 200-Day Moving Average | 3.2121 |
| 50-Day Moving Average | 5.0854 |
| 20-Day Moving Average | 5.48 |
| 10-Day Moving Average | 5.895 |
| Average True Range | 0.5343 |
| ADX | 26.71 |
| +DI | 27.4402 |
| -DI | 19.2959 |
| Chandelier Exit (Long, 3 ATRs ) | 5.1471 |
| Chandelier Exit (Short, 3 ATRs ) | 6.1229 |
| Upper Bollinger Band | 6.501 |
| Lower Bollinger Band | 4.459 |
| Percent B (%b) | 0.65 |
| BandWidth | 37.262774 |
| MACD Line | 0.2876 |
| MACD Signal Line | 0.2784 |
| MACD Histogram | 0.0092 |
| Fundamentals | Value |
|---|---|
| Market Cap | 115.97 Million |
| Num Shares | 20.1 Million |
| EPS | -0.81 |
| Price-to-Earnings (P/E) Ratio | -7.14 |
| Price-to-Sales | 1.39 |
| Price-to-Book | 4.30 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.53 | ||||
| Resistance 3 (R3) | 6.52 | 6.26 | 6.41 | ||
| Resistance 2 (R2) | 6.26 | 6.07 | 6.27 | 6.36 | |
| Resistance 1 (R1) | 6.02 | 5.95 | 5.89 | 6.03 | 6.32 |
| Pivot Point | 5.76 | 5.76 | 5.70 | 5.77 | 5.76 |
| Support 1 (S1) | 5.52 | 5.57 | 5.39 | 5.53 | 5.24 |
| Support 2 (S2) | 5.26 | 5.45 | 5.27 | 5.20 | |
| Support 3 (S3) | 5.02 | 5.26 | 5.16 | ||
| Support 4 (S4) | 5.03 |
